Back to News

Medication Withdrawals

February 28, 2020

The FDA announced the request to voluntarily withdraw Belviq, Belviq XR (lorcaserin) from the U.S. market because a safety clinical trial showed an increased occurrence of cancer. Eisai, the manufacturer, has submitted a request to voluntarily withdraw the drug.

Clinical Services will be conducting a drug recall mailing to potentially impacted members and providers. 


Property Value
 Products  Belviq, Belviq XR
 Manufacturer  Eisai
 Withdrawal identification date  02/13/2020
 Affected NDCs  62856-0529-60, 62856-0535-30
 Look back period  10/16/2019  - 2/13/2020
 Target population for clinical mailing  All
 Mailing type  Members and Providers
 Data release  SS00005114
 Fulfillment due date for NCQA compliance  On or before: 3/4/2020